Effects of BRAF- and MEK-Inhibitor Combinations in sensitive and resistant NRAS-mutated Melanoma Cell Lines

被引：0
|
作者：
Schulz, A. [1 ,2 ]
Dinter, L. [1 ,2 ]
Karitzky, P. C. [1 ,2 ]
Tunger, A. [2 ,3 ]
Mueller, A. [4 ]
Kaeubler, T. [1 ,2 ]
Wehner, R. [2 ,3 ]
Niessner, H. [5 ]
Wanke, I. [5 ]
Beissert, S. [1 ,2 ]
Seliger, B. [4 ]
Schmitz, M. [2 ,3 ]
Meier, F. [1 ,2 ]
Westphal, D. [1 ,2 ]
机构：
[1] Tech Univ Dresden, Fac Med, Dept Dermatol, Dresden, Germany
[2] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Dermatol, Dresden, Germany
[3] Tech Univ Dresden, Inst Immunol, Fac Med, Dresden, Germany
[4] Martin Luther Univ Halle Wittenberg, Inst Med Immunol, Halle, Germany
[5] Univ Tubingen, Div Dermatooncol, Dept Dermatol, Tubingen, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2021年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
FV44
引用
收藏
页码：29 / 29
页数：1
相关论文
共 50 条
  • [1] Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor
    Kusters-Vandevelde, Heidi V. N.
    Willemsen, Annelieke E. C. A. B.
    Groenen, Patricia J. T. A.
    Kusters, Benno
    Lammens, Martin
    Wesseling, Pieter
    Djafarihamedani, Melika
    Rijntjes, Jos
    Delye, Hans
    Willemsen, Michel A.
    van Herpen, Carla M. L.
    Blokx, Willeke A. M.
    [J]. ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2014, 2
  • [2] Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor
    Heidi VN Küsters-Vandevelde
    Annelieke ECAB Willemsen
    Patricia JTA Groenen
    Benno Küsters
    Martin Lammens
    Pieter Wesseling
    Melika Djafarihamedani
    Jos Rijntjes
    Hans Delye
    Michel A Willemsen
    Carla ML van Herpen
    Willeke AM Blokx
    [J]. Acta Neuropathologica Communications, 2
  • [3] Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma
    Niessner, Heike
    Huesch, Anna
    Kosnopfel, Corinna
    Meinhardt, Matthias
    Westphal, Dana
    Meier, Friedegund
    Schilling, Bastian
    Sinnberg, Tobias
    [J]. CANCERS, 2023, 15 (23)
  • [4] The combined BRAF and MEK Therapy as a new Therapeutic Approach for NRAS-mutated Melanoma
    Karitzky, P. C.
    Niessner, H.
    Wanke, I.
    Beissert, S.
    Meier, F.
    Westphal, D.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 7 - 8
  • [5] First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor
    Bickel, Angelika
    Diem, Stefan
    Flatz, Lukas
    Stinn, Bjorn
    Siano, Marco
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (01) : 276 - 278
  • [6] Targeting the persistent activation of mammalian target of rapamycin in BRAF- and NRas-mutated melanoma as a novel therapeutic strategy
    Carroll, B.
    Lovat, P.
    Korolchuk, V.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (05) : E31 - E31
  • [7] BINIMETINIB MEK 1/2 inhibitor Treatment of NRAS-mutated melanoma Treatment of ovarian cancer
    Gras, J.
    [J]. DRUGS OF THE FUTURE, 2015, 40 (03) : 157 - 165
  • [8] Three Patients with metastatic NRAS mutated Melanoma treated with a Combination of MEK-Inhibitor and T-VEC
    Mueller, V.
    Utikal, J.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 78 - 78
  • [9] Inhibition of FGF receptors for effective treatment of BRAF- and BRAF/MEK inhibitor-resistant melanoma cells
    Graf, S. A.
    Strieder, A.
    Meierjohann, S.
    Heppt, M. V.
    Kammerbauer, C.
    Berking, C.
    [J]. EXPERIMENTAL DERMATOLOGY, 2017, 26 (03) : E92 - E92
  • [10] Dropped-head syndrome in a patient under treatment with the MEK inhibitor trametinib for NRAS-mutated metastatic melanoma
    Kleemann, J.
    Hrgovic, I.
    Hempel, K.
    Kaufmann, R.
    Meissner, M.
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2018, 43 (02) : 195 - 196
12345